Related Experiment Video

Updated: Jun 1, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K

Sacubitril/Valsartan for Blood Pressure Lowering in Non-Dialysis-Dependent Chronic Kidney Disease Stage 3-5 Patients

Yu Yan1, Xiaomin Li2, Juan Cao3

  • 1Department of Nephrology, Southeast University Zhongda Hospital, Southeast University School of Medicine, Nanjing, China.

Journal of Clinical Hypertension (Greenwich, Conn.)
|January 18, 2025
PubMed

Insights

Sacubitril/Valsartan effectively lowers blood pressure in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) stages 3-5 and hypertension. The treatment demonstrated a good safety profile with significant blood pressure reduction and no major adverse renal or electrolyte changes.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a common complication in non-dialysis-dependent chronic kidney disease (NDD-CKD) stages 3-5.
  • Effective blood pressure management is crucial for slowing CKD progression and reducing cardiovascular risk.
  • Current antihypertensive treatments may be insufficient for optimal control in this population.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sacubitril/Valsartan in reducing blood pressure.
  • To assess its impact on blood pressure control and laboratory parameters in NDD-CKD patients with hypertension.
  • To determine the incidence of adverse events associated with Sacubitril/Valsartan use in this cohort.

Main Methods:

  • A multicenter retrospective analysis was conducted from March 2022 to March 2024.
  • Included 459 adult patients with NDD-CKD stages 3-5 and hypertension receiving Sacubitril/Valsartan.
  • Measured blood pressure control, laboratory parameters, and adverse events within 8 weeks post-treatment.

Main Results:

  • Significant reductions in systolic blood pressure (12.17 mmHg), diastolic blood pressure (6.00 mmHg), and pulse pressure (6.67 mmHg) were observed (p < 0.001).
  • No significant changes in serum creatinine, eGFR, or serum potassium levels were noted.
  • Adverse events included worsening renal function (20.92%), hyperkalemia (3.27%), and symptomatic hypotension (10.68%).

Conclusions:

  • Sacubitril/Valsartan significantly lowers blood pressure in patients with NDD-CKD stages 3-5 and hypertension.
  • The drug exhibits a favorable safety profile in this patient group.
  • It represents a viable therapeutic option for managing hypertension in NDD-CKD.

Keywords:
chronic kidney diseaseefficacyhypertensionsacubitril/valsartansafety

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.5K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
482
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
577
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
465
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
616
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K